Patents Issued in April 24, 2003
-
Publication number: 20030077258Abstract: The subject invention pertains to compositions and methods for promoting repair of damaged nerve tissue using nerve grafts and preparation of nerve grafts. The compositions and methods of the subject invention can be employed to restore the continuity of nerve interrupted by disease, traumatic events or surgical procedures. Compositions of the subject invention comprise one or more chondroitin sulfate proteoglycan (CSPG)-degrading enzymes that promote axonal penetration into damaged nerve tissue and nerve graft. The invention also concerns methods for promoting repair of damaged nerve tissue using the present compositions and nerve tissue treated according to such methods. The invention also includes storage solutions for nerve tissue.Type: ApplicationFiled: August 13, 2002Publication date: April 24, 2003Inventor: David F. Muir
-
Publication number: 20030077259Abstract: The present invention provides methods for inducing insulin gene expression in cultured pancreas cells, the method comprising contacting a culture of endocrine pancreas cells expressing a PDX-1 gene and a NeuroD/BETA2 gene with a GLP-1 receptor agonist, wherein the cells have been cultured under conditions such that the cells are in contact with other cells in the culture, thereby inducing insulin gene expression in the cells. The invention also provides high throughput screening methods for modulators of &bgr;-cell function, stable cultures of cells made by the methods of the invention, and methods of treating a human subject using the methods of the invention.Type: ApplicationFiled: October 18, 2001Publication date: April 24, 2003Applicant: The Regents of the University of CaliforniaInventors: Fred Levine, Dominique Gouty, Pamela Itkin-Ansari
-
Publication number: 20030077260Abstract: An implantable device having a body of matrix material made up of insoluble collagen fibrils, and disposed therewithinType: ApplicationFiled: July 2, 2002Publication date: April 24, 2003Applicant: Transkaryotic Therapies, Inc.Inventor: Rochelle Mineau-Hanschke
-
Publication number: 20030077261Abstract: The present invention provides methods and compositions for treating diseases and pathological conditions or processes mediated by undesired and/or uncontrolled angiogenesis (characterized as “angiogenic diseases”) by increasing the in vivo concentration of the A&bgr; peptide, or biologically active fragments or variants of the A&bgr; peptide, within a patient suffering from such diseases, conditions, or processes. The present invention also concerns diagnostic methods and kits for detection and measurement of anti-angiogenic A&bgr; peptide activity in biological fluids and tissues. Such diagnostic methods and kits can be utilized to screen compounds for potential therapeutic activity in the treatment of Alzheimer's disease.Type: ApplicationFiled: August 12, 2002Publication date: April 24, 2003Inventors: Daniel Paris, Michael Mullan
-
Publication number: 20030077262Abstract: Methods and compositions for modulating apoptosis by acting on the c-Jun-N-terminal kinase (JNK) pathway. Assays for the isolation of agents capable of modulating apoptosis, including modulators of the JNK pathway. A member of the Gadd45 protein family that inhibits JNK signaling is a target. Methods and compositions are presented for the preparation and use of novel therapeutic compositions for modulating diseases and conditions associated with elevated or decreased apoptosis.Type: ApplicationFiled: October 2, 2002Publication date: April 24, 2003Inventors: Guido Franzoso, Enrico DeSmaele, Francesca Zazzeroni, Salvatore Papa
-
Publication number: 20030077263Abstract: Antigen-expressing, activated dendritic cells are disclosed. Such dendritic cells are used to present tumor, viral or bacterial antigens to T cells, and can be useful in vaccination protocols. Other cytokines can be used in separate, sequential or simultaneous combination with the activated, antigen-pulsed dendritic cells. Also disclosed are methods for stimulating an immune response using the antigen-expressing, activated dendritic cells.Type: ApplicationFiled: November 14, 2002Publication date: April 24, 2003Applicant: Immunex CorporationInventors: Eugene Maraskovsky, Hilary J. McKenna
-
Publication number: 20030077264Abstract: Methods and compositions prolonging the storage life and/or increasing the safety of a blood product, such as whole blood, red blood cells, white blood cells, platelets, serum and aqueous additive solutions for storage of such blood products are provided. Storage solutions of this invention comprise a composition selected from the group consisting of garlic extract, allicin, other microorganism-growth-inhibiting compounds derived from garlic, and analogs and derivatives of allicin and said other compounds, in an amount effective to inhibit growth of at least one selected microorganism which is a bacterium, virus, fungus or parasite. The storage additive solutions of this invention can increase platelet storage life by at least about 20%, preferably at least about 40%.Type: ApplicationFiled: September 18, 2002Publication date: April 24, 2003Inventor: Laura L. Goodrich
-
Publication number: 20030077265Abstract: The present invention provides an ultrafiltration method for isolation and purification of a proteinase inhibitor extract from plant tissue, preferably potato tubers. The extraction and isolation of the proteinase inhibitor from potatoes begins with the addition of an organic acid, preferably formic acid, and a salt, preferably sodium chloride, to raw potatoes. The mixture is subjected to process steps to extract soluble proteins. Undesired proteins are denatured and removed, resulting in an extract solution suitable for ultrafiltration. The ultrafiltration process comprises two parts, concentration and diafiltration. The concentration part is primarily for dewatering, and as such, acids, salts, and other small molecules are removed concurrent to concentration. An ideal ultrafiltration membrane composition comprises regenerated cellulose with a nominal molecular weight cut-off of 10,000 Dalton.Type: ApplicationFiled: September 13, 2001Publication date: April 24, 2003Inventors: Rod Ausich, Robert Stomp, Fayad Z. Sheabar
-
Publication number: 20030077266Abstract: The present invention relates to the treatment of cancerous conditions in mammals by the administration to the site of disease compositions containing serine protease inhibitor. The cancerous conditions include osteocarcinomas, melanoma, Karopsi sarcoma and keratosis. The compositions are also useful to relieve the pain associated with the disease.Type: ApplicationFiled: October 19, 2001Publication date: April 24, 2003Inventors: John Lezdey, K. Anne Kronis, Darren Lezdey
-
Publication number: 20030077267Abstract: The present invention provides the identification and characterization of two components of a recombinant preparation of DNase. These components are the purified deamidated and non-deamidated human DNases. Taught herein are the separation of these components and the use of the non-deamidated species as a pharmaceutical per se, and in particular in compositions wherein the species is disclosed within a plastic vial, for use in administering to patients suffering from pulmonary distress.Type: ApplicationFiled: May 22, 2002Publication date: April 24, 2003Applicant: Genentech, Inc.Inventors: John Frenz, Steven J. Shire, Mary B. Sliwkowski
-
Publication number: 20030077268Abstract: The present invention provides a procaryotic host cell stably transformed or transfected by a vector including a DNA sequence encoding for purine nucleoside phosphorylase or hydrolase. The transformed or transfected procaryotic host cell can be used in combination with a purine substrate to treat tumor cells and/or virally infected cells.Type: ApplicationFiled: July 18, 2002Publication date: April 24, 2003Inventors: Eric J. Sorscher, William B. Parker, William Waud, Vijayakrishna K. Gadi, Leonard L. Bennett
-
Publication number: 20030077269Abstract: The use of sphingomyelinase to increase the levels of skin and mucosal ceramides, as well as dermatological and cosmetic compositions containing same which are suitable for topical application are disclosed.Type: ApplicationFiled: May 22, 2001Publication date: April 24, 2003Applicant: VSL Pharmaceuticals Inc.Inventors: Renata Maria Anna Cavaliere Vesely, Claudio De Simone
-
Publication number: 20030077270Abstract: A method for producing protein compositions comprising fibrinogen and fibronectin is disclosed, wherein a fibrinogen and fibronectin-containing starting solution is treated with a precipitating composition which comprises two different components that modify the solubility of fibrinogen and/or fibronectin, so that in a single-step precipitation a precipitate is formed which comprises fibrinogen and fibronectin, and the precipitate formed optionally is further treated by methods known per se.Type: ApplicationFiled: November 19, 2002Publication date: April 24, 2003Inventors: Thomas Seelich, Ralf Broermann
-
Publication number: 20030077271Abstract: The use of coagulation factor VII-activating protease (FSAP) for the prophylaxis and/or therapy of vasoproliferative disorders or oncoses is described. Reference is made in particular to the use of the protease for retinopathy, neuropathy, rheumatoid arthritis, psoriasis, endometriosis, bronchitis (especially chronic) or chronic inflammations in the gastrointestinal tract.Type: ApplicationFiled: September 26, 2002Publication date: April 24, 2003Inventors: Christian Kannemeier, Juergen Roemisch, Klaus T. Preissner, Sandip Kanse
-
Publication number: 20030077272Abstract: Proteinaceous gels having visualization agents and methods of use thereof are disclosed herein. Further, polymeric crosslinking agents are disclosed that have an inert water soluble polymeric component, biodegradable components, functional components reactive with chemical groups on a protein, for example, amine or thiol groups. The inert polymeric component may be flanked at each end with a biodegradable component which is flanked at each end with a protein reactive functional component. A polymeric crosslinking agent is disclosed having a biodegradable component, polyalkylene oxide, and at least three reactive functional groups that are each capable of forming a covalent bond in water with at least one functional group such as an amine, thiol, or carboxylic acid.Type: ApplicationFiled: November 13, 2002Publication date: April 24, 2003Applicant: Incept LLCInventor: Chandrashekhar P. Pathak
-
Publication number: 20030077273Abstract: Provided herein are methods of treating antibody-mediated pathologies such as autoimmune diseases (e.g., SLE, ITP, and thyroiditis) using agents which inhibit CD21/C3d interaction to ameliorate one or more symptoms of an antibody-mediated pathology. Also provided herein are methods for delaying the development of antibody-mediated pathologies using agents that inhibit CD21/C3d interaction to effect such delay.Type: ApplicationFiled: May 17, 2002Publication date: April 24, 2003Inventors: Matthew D. Linnik, Mary-Ann Campbell
-
Publication number: 20030077274Abstract: The present invention provides methods of delaying development of CEA-associated tumors using the anti-idiotype antibody 3H1, particularly in high-risk individuals.Type: ApplicationFiled: June 3, 2002Publication date: April 24, 2003Inventors: Malaya Chatterjee, Kenneth A. Foon, Sunil K. Chatterjee
-
Publication number: 20030077275Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).Type: ApplicationFiled: August 5, 2002Publication date: April 24, 2003Applicant: IDEC Pharmaceuticals CorporationInventors: Nabil Hanna, Roland Anthony Newman, Mitchell Elliot Reff
-
Publication number: 20030077276Abstract: Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM2.Type: ApplicationFiled: July 16, 2002Publication date: April 24, 2003Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kazuyasu Nakamura, Masamichi Koike, Kenya Shitara, Nobuo Hanai, Yoshihisa Kuwana, Mamoru Hasegawa
-
Publication number: 20030077277Abstract: The invention is composed of monoclonal human MN antibodies or MN antibody fragments that target the GEEDLP repeat within the proteoglycan domain. The proteoglycan domain of the MN cell surface protein contains four of these identical GEEDLP repeats. Binding to the desired epitope is verified by competition ELISA, where ELISA signal can be attenuated by co-incubation with a peptide containing this repeat (PGEEDLPGEEDLP). This inhibition of binding can also be verified using Biacore assays, where binding of desired antibodies to immobilized MN or proteoglycan peptides can be inhibited by the peptide repeat. In addition to binding to the peptide repeat, human anti-MN antibodies can inhibit the cell adhesion of CGL-1 cells to MN coated plastic plates. Human anti-MN antibodies have been used to diagnose and quantify MN expression in cancer cells and tumors using FACS and immunohistochemical methods.Type: ApplicationFiled: October 18, 2002Publication date: April 24, 2003Inventors: Toshihiko Takeuchi, Nathalie Dubois-Stringfellow, John E. Murphy, Julie Rinkenberger
-
Publication number: 20030077278Abstract: Methods to inhibit inflammation and macrophage infiltration following spinal cord injury are disclosed along with methods to modulate TNF&agr; release from cells expressing &agr;d are disclosed.Type: ApplicationFiled: June 26, 2001Publication date: April 24, 2003Applicant: ICOS CorporationInventors: W. Michael Gallatin, Monica Van der Vieren
-
Publication number: 20030077279Abstract: Methods included herein describe the treatment of atherosclerosis and other vascular diseases such as thrombosis, restenosis after angioplasty and/or stenting, and vein-graft disease after bypass surgery, by inhibition of the expression or biologic activity of Toll-like receptor-4 (TLR-4). Also included is an intravascular device coated with a compound that inhibits TLR-4; thereby imparting an improved efficacy to the device. TLR-4 cell signal transduction is at least partially responsible for the manifestation, continuation, and/or worsening of atherosclerosis and other forms of vascular disease. The present invention provides several means with which to inhibit this signal transduction pathway.Type: ApplicationFiled: April 23, 2002Publication date: April 24, 2003Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Moshe Arditi, Tripathi Rajavashisth, Prediman K. Shah
-
Publication number: 20030077280Abstract: This invention provides a monoclonal antibody which specifically recognizes and forms a complex with a protein located on the surface of activated T cells and thereby inhibits T cell activation of B cells. This invention also provides the monoclonal antibody 5c8 (ATCC Accession No. ______).Type: ApplicationFiled: June 25, 2002Publication date: April 24, 2003Applicant: The Trustees of Columbia University In The City Of New YorkInventors: Seth Lederman, Leonard Chess, Michael J. Yellin
-
Publication number: 20030077281Abstract: The present invention relates generally to immunointeractive molecules and their use inter alia in the detection and/or purification of T-cell antigen binding molecules (TABMs). The ability to determine the presence and levels of particular TABMs provides a useful diagnostic procedures for a variety of disease conditions.Type: ApplicationFiled: July 8, 2002Publication date: April 24, 2003Inventors: Robert E. Cone, George M. Georgiou, Colin H. Little
-
Publication number: 20030077282Abstract: The invention relates generally to the field of immunology, in particular, to bispecific antibodies. Methods for designing a bispecific antibody for use in treating diseases relating to the immune system are disclosed. Specific examples relate to bispecific antibodies which recognize an activating receptor and an inhibiting receptor.Type: ApplicationFiled: October 11, 2002Publication date: April 24, 2003Inventors: Michael Eric Bigler, Holly Marie Cherwinski, Joseph H. Phillips
-
Publication number: 20030077283Abstract: A method for treatment of psoriasis and other inflammatory skin conditions, comprising applying topically a composition containing as active ingredient an antibody neutralizing human Interleukin-8 (IL-8) biological activity together with a pharmaceutically acceptable carrier. The invention also includes a pharmaceutical composition for treating inflammatory skin conditions. The pharmaceutical composition includes antibodies that neutralize human Interleukin-8 (IL-8) biological activity.Type: ApplicationFiled: September 21, 2001Publication date: April 24, 2003Inventor: George Q. W. Ye
-
Publication number: 20030077284Abstract: Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods.Type: ApplicationFiled: August 13, 2002Publication date: April 24, 2003Applicant: National Jewish Medical and Research CenterInventors: Barbara J. Vilen, John C. Cambier
-
Publication number: 20030077285Abstract: p75/AIRM1 is expressed on myeloid cells at stages of differentiation and determination of its presence is useful in monitoring cellular proliferation and determining proliferative states of cells, especially myeloid cells in diseases such as chronic myeloid leukemia. Ligands such as antibody molecules, for instance the QA79 monoclonal antibody deposited under accession number ICLC No. PD99003, are useful for methods of diagnosis and treatment, e.g. by way of inhibition of cellular proliferation and induction of apoptosis in cells.Type: ApplicationFiled: October 2, 2002Publication date: April 24, 2003Inventors: Roberto Biassoni, Alessandro Moretta, Lorenzo Moretta, Maria Cristina Mingari
-
Publication number: 20030077286Abstract: The present invention concerns TCR ligands with immunomodulatory properties, as well as methods of identifying such ligands and of using such ligands to modulate T cell effector responses.Type: ApplicationFiled: July 10, 2002Publication date: April 24, 2003Inventors: Ronald N. Germain, Luigi Racioppi, Franca Ronchese-Le Gros
-
Publication number: 20030077287Abstract: A method of improving specific immune responses to smal immunogens, haptens, has been developed by changing the linkage between the hapten and carrier being used for immunization. High affinity antibodies to the hapten cotinine have been produced using this method. Antibodies to a glycated protein have also been developed, utilizing an immunogen which is composed of a glycated peptide mimic of the glycated peptide sequence which is the target epitope, wherein the peptide mimic is constructed to conformationally mimic the conformation of the peptide in the native protein, the peptide mimic contains no charged groups or other immunodominant group, and the peptide mimic is connected to a spacer sequence equivalent to a peptide spacer of between one and thirty amino acids in length, which serves to position the peptide epitope in a conformation that approximates its conformation in the native protein. In a further embodiment the peptide mimic and spacer are linked to a carrier molecule.Type: ApplicationFiled: August 21, 2002Publication date: April 24, 2003Applicant: Serex, Inc.Inventors: Judith Fitzpatrick, Regina Lenda
-
Publication number: 20030077288Abstract: The present invention relates to the isolation of cell- or tissue-specific F-box proteins which are involved in ubiquitin-mediated protein degradation in a specific cell- or tissue-type. Accordingly, the invention provides nucleic acids and the proteins encoded by said nucleic acids which play a role in the ubiquitinylation and subsequent degradation of substrate proteins and in regulating cell proliferation, cell differentiation, and cell survival.Type: ApplicationFiled: January 16, 2002Publication date: April 24, 2003Inventors: Alfred L. Goldberg, Marcelo D. Gomes, Stewart H. Lecker, R. Thomas Jagoe
-
Publication number: 20030077289Abstract: The present invention is directed to methods and compositions for enhancing an immune response in an animal to a disease by administering an immune effector cell comprising a cell penetrating peptide associated with an antigen for the disease. In a specific embodiment, the immune effector cell is a dendritic cell comprising a cell penetrating peptide associated with an antitumor antigen for cancer immunotherapy.Type: ApplicationFiled: February 15, 2002Publication date: April 24, 2003Inventor: Rong-Fu Wang
-
Publication number: 20030077290Abstract: The invention relates to a hypoallergenic immunogenic molecule derived from the Phl p 6 allergen, wherein the Phl p6 molecule has an N-terminal and/or C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity. The invention also relates to a hypoallergenic immunogenic combination of molecules derived from the Phl p 6 allergen, comprising (i) a Phl p 6 molecule having an N-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, and (ii) a Phl p 6 molecule having a C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, which two molecules together encompass the complete sequence of Phl p 6. The invention further relates to the use of the hypoallergenic immunogenic molecule or molecule mixture in hyposensitization and diagnosis.Type: ApplicationFiled: May 10, 2002Publication date: April 24, 2003Applicant: Pharmacia Diagnostics ABInventors: Rudolf Valenta, Susanne Vrtala, Sabine Stumvoll, Hans Gronlund, Monika Grote, Luca Vangelista, Annalisa Pastore, Wolfgang R. Sperr, Peter Valent, Dietrich Kraft
-
Publication number: 20030077291Abstract: The present invention relates to the use of a preparation of an active enamel matrix substance, such as an amelogenin, for the manufacture of a pharmaceutical composition for modulating an immune response. The composition can be used in preventing and/or treating a condition or disease in a mammal that is characterised by said mammal presenting an imbalance in its native immune response to an internal and/or external stimuli, i.e. wherein at least a part of said mammal's immune system is stimulated non-discriminatingly, reacts hypersensitively to said immunogen, or fails to react to said stimuli. Said condition can typically either be systemic or local, such as a systemic and/or post-traumatic whole-body inflammation or an autoimmune disease.Type: ApplicationFiled: September 12, 2002Publication date: April 24, 2003Inventors: Stina Gestrelius, Petter Lyngstadaas
-
Publication number: 20030077292Abstract: The present invention relates to compositions and methods for cancer therapies and diagnostics, including but not limited to, cancer markers. In particular, the present invention provides tumor antigens associated with specific cancers and diagnostic assays for the detection of such antigens and associated autoantibodies as indicative of the presence of specific cancers. The present invention further provides cancer immunotherapy utilizing the tumor antigens of the present invention.Type: ApplicationFiled: September 16, 2002Publication date: April 24, 2003Applicant: The Regents of the University of MichiganInventors: Samir M. Hanash, Franck Brichory
-
Publication number: 20030077293Abstract: Streptococcus polypeptides and polynucleotides encoding them are disclosed. Said polypeptides may be useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.Type: ApplicationFiled: June 20, 2001Publication date: April 24, 2003Inventors: Josee Hamel, Catherine Ouellet, Nathalie Charland, Denis Martin, Bernard Brodeur
-
Publication number: 20030077294Abstract: The present invention provides novel antigenic preparations comprising proteinaceous material associated with adenylate cyclase activity in cultures of B.pertussis, the said preparations being useful as components of acellular whooping cough vaccines. The invention further provides methods for the isolation of such antigenic preparations.Type: ApplicationFiled: September 16, 2002Publication date: April 24, 2003Applicant: Medeva Pharma LimitedInventors: Pavel Novotny, Juan Antonio Montaraz Crespo, Juraj Ivanyi
-
Publication number: 20030077295Abstract: Dendritic polymer conjugates which are useful drug delivery systems for carrying platinum containing anti-tumor agents to malignant tumors are prepared by obtaining a dendritic polymer having functional groups which are accessible to a platinum containing compound capable of interacting with the functional groups, contacting the dendritic polymer with the platinum containing compound, and reacting the dendritic polymer with the platinum containing compound. The dendritic polymer platinates may be administered intravenously, orally, parentally, subcutaneously or topically to an animal having a malignant tumor in an amount which is effective to inhibit growth of the malignant tumor. The dendritic polymer platinates exhibit high drug efficiency, high drug carrying capacity, good water solubility, good stability on storage, reduced toxicity, and improved anti-tumor activity in vivo.Type: ApplicationFiled: July 7, 1998Publication date: April 24, 2003Inventors: NAVID MALIK, RUTH DUNCAN
-
Publication number: 20030077296Abstract: A composition for topical application to female genitalia to stimulate and enhance sensitivity during coitus is formed in a gel which includes propylene glycol, aloe barbadensis leaf juice, hydroxyethylcellulose, L'Arginine, menthol, methylparaben, Lepidium meyenii root extract and/or Anemopegma mirandum extract.Type: ApplicationFiled: October 24, 2001Publication date: April 24, 2003Inventors: Michael G. Denton, Michael G. Denton, Gerry R. Hurst
-
Publication number: 20030077297Abstract: The present invention pertains to pharmaceutical formulations and systems for delivery of active agents, wherein a first fraction of an active agent is suspended in a vehicle and a second fraction of active agent is solubilized in the vehicle, with the suspended fraction representing about 5 wt. % to about 80 wt. % of the active agent and the second fraction representing about 20 wt. % to about 95 wt. % of the active agent. One or more additional active agents, which may be fully solubilized, partially solubilized, or suspended, may also be present. The first and second fractions of the active agent may or may not have different release profiles. Generally, a significant fraction of the solubilized drug will release rapidly, providing for rapid onset, while the suspended drug may be formulated for delayed and/or sustained release.Type: ApplicationFiled: February 11, 2002Publication date: April 24, 2003Inventors: Feng-Jing Chen, Srinivasan Venkateshwaran, Steven L. Krill, Mahesh V. Patel
-
Publication number: 20030077298Abstract: Disorders of the skin and mucous membrane that have a disrupted or dysfunctional epidermal barrier, disturbed differentiation, or inflammation are treated or prevented by topical application of compounds that are activators of peroxisome proliferator-activated receptor-delta.Type: ApplicationFiled: April 12, 2002Publication date: April 24, 2003Applicant: The Regents of the University of California, a California CorporationInventors: Peter M. Elias, Kenneth R. Feingold, Matthias Schmuth
-
Publication number: 20030077299Abstract: A dilatant composition comprises (A) an o/w emulsion comprising an ionic surfactant, a water phase, and an oil phase which comprises a ceramide or a linear or branched, saturated or unsaturated C12-C32 fatty acid, wherein the oil phase is in a form of oil droplets having an average droplet size of from 0.01 to 0.2 &mgr;m; and (B) a nonionic, water-soluble polymer having an average molecular weight of at least 300,000.Type: ApplicationFiled: April 17, 2002Publication date: April 24, 2003Applicant: KAO CORPORATIONInventors: Hidetaka Iwai, Tomohiko Sano
-
Publication number: 20030077300Abstract: The invention relates to pharmaceutical drug compositions and preparations that are narcotic antagonists and analgesics, specifically opioids, more specifically morphine and its pharmaceutically active derivatives, analogues, homologues, and metabolites, and still more specifically hydromorphone and butorphanol. This invention also relates to pharmaceutical drug delivery devices, specifically to devices for the intranasal administration of drugs classified as controlled substances. The invention also relates to the field of acute pain management through pharmaceutical intervention, particularly as practiced in an institutional setting, such as a hospital.Type: ApplicationFiled: May 24, 2002Publication date: April 24, 2003Inventor: Daniel P. Wermeling
-
Publication number: 20030077301Abstract: Provided is a topical pharmaceutical composition for the treatment of inflammatory dermatoses, including acne vulgaris, together with methods for its use. The composition and methods involve the topical use of an active agent effective in the treatment of inflammatory dermatoses plus a permeation-enhancing base that, in one embodiment, gives the composition a pH of about 8.0 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5.Type: ApplicationFiled: June 21, 2002Publication date: April 24, 2003Inventors: Howard I. Maibach, Eric C. Luo, Tsung-Min Hsu
-
Publication number: 20030077302Abstract: The present invention relates to ophthalmic compositions in the form of suspension gels of the free acid of the diclofenamide for treating glaucoma. The invention also relates to the use of suspension gels containing the free acid of the diclofenamide for treating primary and/or secondary open-angle glaucomas, for reducing the intra-ocular pressure and for treating ocular hypertension.Type: ApplicationFiled: September 30, 2002Publication date: April 24, 2003Inventors: Gudrun Claus-Herz, Gunther Bellmann
-
Publication number: 20030077303Abstract: The present invention claims and discloses a pharmaceutical composition suitable for oral administration, in form of an emulsion pre-concentrate, comprising (i) a compound of formula (I); (ii) one or more surfactants; (iii) optionally an oil or semi-solid fat; said composition forming an in-situ oil-in-water emulsion upon contact with aqueous media such as gastrointestinal fluids. The composition may optionally also comprise one or more short-chain alcohols. The pharmaceutical composition is useful in the treatment of pain and inflammation.Type: ApplicationFiled: September 5, 2002Publication date: April 24, 2003Inventors: Christina Holmberg, Britta Siekmann
-
Publication number: 20030077304Abstract: Composition for topical administration comprising (a) a corticosteroid, and (b) a drying agent.Type: ApplicationFiled: November 12, 2002Publication date: April 24, 2003Inventor: Michael E. McCadden
-
Publication number: 20030077305Abstract: Angiogenic endothelial cells are selectively targeted with lipid/DNA complexes or cationic liposomes containing a substance which affects the targeted cells by inhibiting or promoting their growth. A site of angiogenesis can be precisely located by administering cationic liposomes containing a detectable label. The complexes may comprise nucleotide constructs which are comprised of promoters which are selectively and exclusively activated in the environment of an angiogenic endothelial cell.Type: ApplicationFiled: November 22, 2002Publication date: April 24, 2003Inventors: Donald M. McDonald, John McLean, O. Gavin Thurston, Peter Baluk
-
Publication number: 20030077306Abstract: Novel emulsion compositions which improve the rate and/or extent of absorption of drugs are disclosed. The novel emulsion compositions of the present invention include drug-containing emulsions adsorbed onto solid particles which may be further formulated into solid dosage forms, methods of preparing such emulsion compositions and their uses thereof. The emulsion compositions and their dosage forms improve the drug-load and the bioavailability of a wide range of drugs including drugs that are known or suspected of having poor bioavailability by the utilization of several different mechanisms.Type: ApplicationFiled: November 25, 2002Publication date: April 24, 2003Inventors: S. Indiran Pather, Sangeeta V. Gupte, Rajendra K. Khankari, John Hontz, Ramya Kumbale
-
Publication number: 20030077307Abstract: The present invention relates to a film-forming barrier composition useful for protecting the skin from body fluids, such as urine, feces, menses. The composition comprises a skin conditioning agent, a viscosity enhancing agent and an oleophilic film-forming agent. Optionally, the lotion may comprise skin care ingredients for treating or maintaining skin health. The composition may be applied to the skin by suitable delivery vehicles, such as absorbent articles or components thereof, sheet materials, pads, bandages, sponges, foam pads, pumps, sprays, depending on the viscosity of the composition.Type: ApplicationFiled: July 3, 2001Publication date: April 24, 2003Applicant: The Procter & Gamble CompanyInventors: Thomas James Klofta, James Anthony Staudigel, George Endel Deckner